跳至主要内容
临床试验/NCT00641524
NCT00641524已完成不适用

Evaluation of Phlebotomy as a Treatment for Non-alcoholic Fatty Liver Disease

University of Western Ontario, Canada2 个研究点 分布在 1 个国家目标入组 45 人开始时间: 2009年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
45
试验地点
2
主要终点
Severity of liver disease

研究概览

简要总结

The purpose of this study is to evaluate the use of phlebotomy (blood taking)as a treatment for patients with non-alcoholic fatty liver disease.

详细描述

In this study phlebotomy will be evaluated as a therapy for non-alcoholic fatty liver disease (NAFLD), a common and important cause of liver disease. Phlebotomy has been used for many years in the treatment of disorders of iron overload such as hemochromatosis, where it is well tolerated and improves symptoms and survival. There is some evidence that it is also effective in treating NAFLD. However, previous studies have not evaluated whether phlebotomy improves liver biopsy findings. We will measure the severity disease in NAFLD patients prior to phlebotomy therapy and again at the end of treatment. This will allow us to accurately determine the benefit of this therapy in these patients.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients 18y or older
  • Diagnosis of Non-alcoholic Fatty Liver Disease

排除标准

  • Unable or unwilling to provide informed consent
  • Alcohol consumption of >10g/day for women and >20g/day for men

结局指标

主要结局

Severity of liver disease

时间窗: 6 months after final treatment

次要结局

  • Severity of metabolic disease(6 months after final treatment)

研究者

发起方
University of Western Ontario, Canada
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验